Literature DB >> 10221661

Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia.

W J Dellow1, S T Chambers, M Lever, H Lunt, R A Robson.   

Abstract

In an ambulatory population of diabetic subjects (Type 1 and Type 2), the urine excretion of the renal osmolyte, glycine betaine, was compared to known markers of glycemic control, renal dysfunction and to the excretion of related betaines, including trigonelline, proline betaine, carnitine and acetyl-carnitine. Of the 85 subjects, 20 patients had urine glycine betaine concentrations above the reference range for normal subjects. Plasma glycine betaine concentrations were within reference ranges for normal subjects. Patients with elevated glycine betaine excretion tended to have lower plasma glycine betaine concentrations, but this did not reach statistical significance. One way analysis of variance found excretion is independent of treatment, duration of diagnosed diabetes, blood pressure and body mass index (BMI). An association between glycine betaine excretion and glycemic control was observed with statistically significant correlations occurring with both plasma glucose (r = 0.43, P < 0.001) and glycated haemoglobin (HbA1c) (r = 0.35, P < 0.005). The excretion of carnitine, acetyl-carnitine and proline betaine were related to glycine betaine excretion (r = 0.49, P < 0.001; r = 0.40, P < 0.001; r = 0.27, P < 0.05, respectively). Urine carnitine and acetyl-carnitine concentrations were also related to plasma glucose concentrations (r = 0.30, P < 0.01). Increased urine retinol binding protein concentrations (RBP), a marker of proximal tubular dysfunction, correlated with elevated urine glycine betaine excretion and plasma HbA1c (r = 0.28, P < 0.01). These results suggest poor glycemic control is associated with the increase in urine glycine betaine, carnitine, acetyl-carnitine and RBP excretion in diabetic patients. However, < 50% of the observed increase in glycine betaine excretion has been accounted for by the variables measured, suggesting other unidentified processes may also be involved.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221661     DOI: 10.1016/s0168-8227(98)00115-6

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  13 in total

1.  Functional role of sodium glucose transporter in high glucose-mediated angiotensin type 1 receptor downregulation in human proximal tubule cells.

Authors:  Rekha Yesudas; Russell Snyder; Thomas Abbruscato; Thomas Thekkumkara
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-30

2.  Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus.

Authors:  Andrew D Patterson; Jessica A Bonzo; Fei Li; Kristopher W Krausz; Gabriel S Eichler; Sadaf Aslam; Xenia Tigno; John N Weinstein; Barbara C Hansen; Jeffrey R Idle; Frank J Gonzalez
Journal:  J Biol Chem       Date:  2011-04-12       Impact factor: 5.157

3.  Thrombospondin-1 mediates distal tubule hypertrophy induced by glycated albumin.

Authors:  Yu-Lin Yang; Lea-Yea Chuang; Jinn-Yuh Guh; Shu-Fen Liu; Min-Yuan Hung; Tung-Nan Liao; Yu-Lun Huang
Journal:  Biochem J       Date:  2004-04-01       Impact factor: 3.857

4.  Acute inhibition of the betaine transporter by ATP and adenosine in renal MDCK cells.

Authors:  Stephen A Kempson; Jason M Edwards; Alyssa Osborn; Michael Sturek
Journal:  Am J Physiol Renal Physiol       Date:  2008-04-30

5.  Effects of orange juice and proline betaine on glycine betaine and homocysteine in healthy male subjects.

Authors:  Wendy Atkinson; Pamela Downer; Michael Lever; Stephen T Chambers; Peter M George
Journal:  Eur J Nutr       Date:  2007-12-04       Impact factor: 5.614

6.  Association of betaine with blood pressure in dialysis patients.

Authors:  Lulu Wang; Mingming Zhao; Wenjin Liu; Xiurong Li; Hong Chu; Youwei Bai; Zhuxing Sun; Chaoqing Gao; Lemin Zheng; Junwei Yang
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-01-25       Impact factor: 3.738

7.  The contrasting relationships between betaine and homocysteine in two clinical cohorts are associated with plasma lipids and drug treatments.

Authors:  Michael Lever; Peter M George; Wendy Atkinson; Jane L Elmslie; Sandy Slow; Sarah L Molyneux; Richard W Troughton; A Mark Richards; Christopher M Frampton; Stephen T Chambers
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

8.  Variability of plasma and urine betaine in diabetes mellitus and its relationship to methionine load test responses: an observational study.

Authors:  Michael Lever; Sandy Slow; David O McGregor; Warwick J Dellow; Peter M George; Stephen T Chambers
Journal:  Cardiovasc Diabetol       Date:  2012-07-11       Impact factor: 9.951

9.  Metabolic profiling in Maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers.

Authors:  Anna L Gloyn; Johan H Faber; Daniel Malmodin; Gaya Thanabalasingham; Francis Lam; Per Magne Ueland; Mark I McCarthy; Katharine R Owen; Dorrit Baunsgaard
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

10.  Assessment of urinary betaine as a marker of diabetes mellitus in cardiovascular patients.

Authors:  Hall Schartum-Hansen; Per M Ueland; Eva R Pedersen; Klaus Meyer; Marta Ebbing; Øyvind Bleie; Gard F T Svingen; Reinhard Seifert; Bjørn E Vikse; Ottar Nygård
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.